Becton, Dickinson and Company (NYSE:BDX) Stock Holdings Lessened by Prudent Man Advisors LLC

Prudent Man Advisors LLC cut its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.1% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,027 shares of the medical instruments supplier’s stock after selling 129 shares during the period. Prudent Man Advisors LLC’s holdings in Becton, Dickinson and Company were worth $1,591,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. McClarren Financial Advisors Inc. lifted its stake in Becton, Dickinson and Company by 4,900.0% in the second quarter. McClarren Financial Advisors Inc. now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 98 shares during the last quarter. Glass Jacobson Investment Advisors llc acquired a new position in Becton, Dickinson and Company in the 2nd quarter valued at $37,000. Altshuler Shaham Ltd bought a new position in shares of Becton, Dickinson and Company in the second quarter worth about $38,000. Tucker Asset Management LLC bought a new stake in shares of Becton, Dickinson and Company in the first quarter valued at approximately $37,000. Finally, Mcmillion Capital Management Inc. acquired a new stake in shares of Becton, Dickinson and Company in the second quarter worth $42,000. Institutional investors and hedge funds own 86.72% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Richard Byrd sold 459 shares of the firm’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $274.48, for a total value of $125,986.32. Following the completion of the transaction, the executive vice president now owns 3,444 shares of the company’s stock, valued at $945,309.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, EVP Richard Byrd sold 459 shares of the stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $274.48, for a total transaction of $125,986.32. Following the completion of the transaction, the executive vice president now directly owns 3,444 shares of the company’s stock, valued at $945,309.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Claire Fraser sold 848 shares of the business’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $281.66, for a total value of $238,847.68. Following the transaction, the director now directly owns 21,608 shares in the company, valued at approximately $6,086,109.28. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Raymond James cut their price objective on shares of Becton, Dickinson and Company from $304.00 to $269.00 and set an “outperform” rating for the company in a research report on Friday, November 10th. StockNews.com assumed coverage on shares of Becton, Dickinson and Company in a research note on Thursday, October 5th. They issued a “hold” rating on the stock. Citigroup lowered their price objective on Becton, Dickinson and Company from $282.00 to $260.00 in a research note on Monday, October 2nd. Piper Sandler lowered their price target on Becton, Dickinson and Company from $305.00 to $280.00 and set an “overweight” rating on the stock in a research report on Friday, November 10th. Finally, Barclays lifted their price objective on Becton, Dickinson and Company from $284.00 to $303.00 and gave the company an “overweight” rating in a report on Monday, August 7th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $282.38.

Becton, Dickinson and Company Stock Down 0.0 %

BDX traded down $0.06 during trading on Monday, hitting $233.21. The company had a trading volume of 258,920 shares, compared to its average volume of 1,177,752. The company has a market capitalization of $67.66 billion, a PE ratio of 47.03, a PEG ratio of 1.88 and a beta of 0.55. The company has a quick ratio of 0.81, a current ratio of 1.31 and a debt-to-equity ratio of 0.57. Becton, Dickinson and Company has a one year low of $225.61 and a one year high of $287.32. The firm’s 50-day moving average price is $256.46 and its 200 day moving average price is $260.56.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 9th. The medical instruments supplier reported $3.42 EPS for the quarter, meeting analysts’ consensus estimates of $3.42. Becton, Dickinson and Company had a return on equity of 13.91% and a net margin of 7.66%. The company had revenue of $5.09 billion for the quarter, compared to analyst estimates of $5.02 billion. During the same period in the previous year, the company posted $2.75 earnings per share. The company’s quarterly revenue was up 6.8% compared to the same quarter last year. As a group, equities analysts expect that Becton, Dickinson and Company will post 12.84 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be issued a $0.95 dividend. The ex-dividend date is Thursday, December 7th. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.91. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.63%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 73.39%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.